CF Europe requests that EMA consider a conditional marketing authorisation for the triple combination
In February, we appealed to the EMA to review the latest triple combination modulator therapy, elexacaftor–tezacaftor–ivacaftor, with a sense of urgency. Today, the urgent need for this therapy could not be greater. People with CF are not more exposed to Covid-19 infection than the rest of the population, yet long-term consequences may be way graver.
CF Europe and its 48 members now appeal to the EMA, Vertex Pharmaceuticals and national authorities, pressing the need for goodwill from all stakeholders, to expediate access to the triple combination therapy for our CF community.
Read our letter to EMA here: 2020-05-19_triple combination_letter to EMA